Across 138 European psychiatry phase 2 & 3 CTIS trials, CRO or specialist vendor support appeared in 54 trials or 39.1%. IQVIA was the most frequently named support provider, appearing in 28 CRO-supported trials, followed by Medidata in 19 and Syneos Health in 14. CRO need rose sharply once trials crossed multi-country and multi-site thresholds: 25 of 26 trials with 5+ countries and 28 of 29 trials with 21+ sites used CRO support.
Among 54 CRO-supported trials, IQVIA appeared in 28 trials or 51.9%. Medidata appeared in 19 of 54 or 35.2%, while Syneos Health appeared in 14 of 54 or 25.9%.
The most active CRO ecosystem is not purely full-service. IQVIA, Syneos, PPD and ICON represent operational support, while Medidata and Signant show how psychiatry trials depend heavily on eClinical, electronic clinical outcome assessment, rater, and scale-management infrastructure.
CRO use was lowest in single-country trials, where 9 of 88 used CRO support (10.2%). It rose to 19 of 23 trials with 2–4 countries (82.6%) and 25 of 26 trials with 5+ countries (96.2%). Site count showed the same threshold effect: 28 of 29 trials with 21+ sites used CRO support.
The strongest operational trigger is not participant count alone. CRO support becomes near-standard when psychiatry programs require broad EU country activation or large site networks, especially above 5 countries or 21 sites.
Depression and treatment-resistant depression generated the largest absolute CRO demand, with 23 of 51 trials CRO-supported (45.1%). The highest proportional CRO use appeared in bipolar disorder or mania (4 of 4, 100.0%), Alzheimer’s/dementia neuropsychiatry (6 of 9, 66.7%), anxiety/trauma-related disorders (3 of 5, 60.0%), and schizophrenia/psychosis (12 of 21, 57.1%).
| Indication group | Trials | CRO-supported | Rate |
|---|---|---|---|
| Bipolar disorder / mania | 4 | 4 | 100.0% |
| Alzheimer’s / dementia neuropsychiatry | 9 | 6 | 66.7% |
| Anxiety / trauma-related disorders | 5 | 3 | 60.0% |
| Schizophrenia / psychosis | 21 | 12 | 57.1% |
| Depression / treatment-resistant depression | 51 | 23 | 45.1% |
| Addiction / substance-use disorders | 15 | 3 | 20.0% |
| Neurodevelopmental / paediatric psychiatry | 11 | 0 | 0.0% |
Depression is the largest commercial and operational CRO opportunity by trial count, but Alzheimer’s/dementia neuropsychiatry, schizophrenia/psychosis, bipolar disorder, and anxiety-related programs show stronger proportional reliance on CRO infrastructure.
The most frequently documented outsourced psychiatry trial functions were eCOA, scale and central rater services in 32 of 138 trials (23.2%), ECG/cardiac safety in 30 of 138 (21.7%), IMP supply and packaging in 30 of 138 (21.7%), and central lab/biomarker/diagnostic testing in 29 of 138 (21.0%).
Psychiatry outsourcing is endpoint-heavy. eCOA, scale licensing, rater training, central rating, ECG safety, and eClinical systems appear alongside classic monitoring and site-management roles, reflecting the importance of standardized psychiatric outcome measurement.
CRO-supported trials generated 256 country-level EU Part II timing records, compared with 99 in non-CRO trials. Median country-level Part II processing time was 105 days in CRO-supported trials versus 67 days in non-CRO trials. Median time from initial CTIS submission to first authorization was 113 days in CRO-supported trials versus 87.5 days in non-CRO trials.
CRO support is associated with broader EU submission coordination rather than shorter approval timelines. In psychiatry phase 2 & 3 trials, CROs appear where CTIS activity spans more countries, more sites, more country-level Part II dossiers, and more operational handoffs.
Two additional operating questions are strongly answerable from the same CTIS dataset: whether CRO demand is sponsor-type dependent, and which European countries carry the highest psychiatry trial site load.
Industry/pharma sponsors used CRO support in 50 of 65 trials (76.9%), compared with 4 of 70 academic or hospital-sponsored trials (5.7%).
The top five countries by allocated sites were Poland (208), Bulgaria (203), Spain (157), Germany (143), and France (141), together representing 852 of 1,642 sites (51.9%).
The practical market signal is clear: CRO demand is concentrated in industry-sponsored psychiatry development and in EU geographies with dense outpatient psychiatric site networks, especially Central and Eastern Europe plus Spain, Germany, and France.
CRO means contract research organization or specialist trial support provider. CTIS means Clinical Trials Information System, the EU portal used for clinical trial submissions under the EU Clinical Trials Regulation. EU Part II refers to the country-specific assessment layer covering local trial conduct, sites, consent materials, and national requirements. eCOA means electronic clinical outcome assessment; EDC means electronic data capture; IxRS means interactive response technology used for randomization and trial supply workflows; IMP means investigational medicinal product.